Status:

COMPLETED

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Lead Sponsor:

Duke University

Collaborating Sponsors:

Lantheus Medical Imaging

Conditions:

Healthy

Eligibility:

All Genders

18-45 years

Phase:

NA

Brief Summary

The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintainin...

Eligibility Criteria

Inclusion

  • healthy male or female subjects between 18-45 years of age

Exclusion

  • Pregnant and lactating females
  • known renal impairment
  • allergy to gadolinium-based contrast
  • metallic implanted devices
  • claustrophobia.

Key Trial Info

Start Date :

August 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2013

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT01431300

Start Date

August 1 2011

End Date

July 1 2013

Last Update

December 10 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Duke University Medical Center

Durham, North Carolina, United States, 27710

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants | DecenTrialz